Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Vernero

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Revista Espanola De Enfermedades Digestivas|February 15, 2020
Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational studyDavide Giuseppe Ribaldone, Gian Paolo Caviglia, Rinaldo Pellicano, et al.
Scandinavian Journal of Gastroenterology|April 5, 2019
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysisDavide Giuseppe Ribaldone, Rinaldo Pellicano, Marta Vernero, et al.
Journal of Clinical Medicine|February 24, 2024
Prevalence and Clinical Impact of Immune-Mediated Inflammatory Diseases in Patients with Inflammatory Bowel Disease: Results from a Large Retrospective Observational StudyMarta Vernero, Simone Saibeni, Davide Scalvini, et al.
Scandinavian Journal of Gastroenterology|December 13, 2017
The adherence to the therapy in inflammatory bowel disease: beyond the number of the tabletsDavide Giuseppe Ribaldone, Marta Vernero, Giorgio Maria Saracco, et al.
Journal of Clinical Medicine|November 14, 2023
Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel DiseaseMarta Vernero, Cristina Bezzio, Davide G Ribaldone, et al.
Clinical Oral Investigations|November 24, 2025
Impact of lifestyle behaviors on clinical outcomes of steps 1 and 2 of periodontal therapy in stage iii-iv periodontitis: a cohort studyFederica Romano, Giacomo Baima, Melanie Llerena-Velasquez, et al.
Journal of Clinical Medicine|January 11, 2025
Type 2 Diabetes Mellitus in Inflammatory Bowel Disease Patients: A Case-Control Study Through a Long Follow-Up PeriodBenedetta Zaccardi, Angelo Armandi, Gian Paolo Caviglia, et al.
Scandinavian Journal of Gastroenterology|November 7, 2019
Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann IndexDavide Giuseppe Ribaldone, Gian Paolo Caviglia, Rinaldo Pellicano, et al.
Journal of Clinical Medicine|August 7, 2021
Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective StudyDavide Giuseppe Ribaldone, Elisa Tribocco, Chiara Rosso, et al.
Frontiers in Immunology|April 10, 2020
Preventing Infections by Encapsulated Bacteria Through Vaccine Prophylaxis in Inflammatory Bowel DiseaseMarco Vincenzo Lenti, Caterina Mengoli, Marta Vernero, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Revista Espanola De Enfermedades Digestivas|February 15, 2020
Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational studyDavide Giuseppe Ribaldone, Gian Paolo Caviglia, Rinaldo Pellicano, et al.
Scandinavian Journal of Gastroenterology|April 5, 2019
Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysisDavide Giuseppe Ribaldone, Rinaldo Pellicano, Marta Vernero, et al.
Journal of Clinical Medicine|February 24, 2024
Prevalence and Clinical Impact of Immune-Mediated Inflammatory Diseases in Patients with Inflammatory Bowel Disease: Results from a Large Retrospective Observational StudyMarta Vernero, Simone Saibeni, Davide Scalvini, et al.
Scandinavian Journal of Gastroenterology|December 13, 2017
The adherence to the therapy in inflammatory bowel disease: beyond the number of the tabletsDavide Giuseppe Ribaldone, Marta Vernero, Giorgio Maria Saracco, et al.
Journal of Clinical Medicine|November 14, 2023
Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel DiseaseMarta Vernero, Cristina Bezzio, Davide G Ribaldone, et al.
Clinical Oral Investigations|November 24, 2025
Impact of lifestyle behaviors on clinical outcomes of steps 1 and 2 of periodontal therapy in stage iii-iv periodontitis: a cohort studyFederica Romano, Giacomo Baima, Melanie Llerena-Velasquez, et al.
Journal of Clinical Medicine|January 11, 2025
Type 2 Diabetes Mellitus in Inflammatory Bowel Disease Patients: A Case-Control Study Through a Long Follow-Up PeriodBenedetta Zaccardi, Angelo Armandi, Gian Paolo Caviglia, et al.
Scandinavian Journal of Gastroenterology|November 7, 2019
Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann IndexDavide Giuseppe Ribaldone, Gian Paolo Caviglia, Rinaldo Pellicano, et al.
Journal of Clinical Medicine|August 7, 2021
Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective StudyDavide Giuseppe Ribaldone, Elisa Tribocco, Chiara Rosso, et al.
Frontiers in Immunology|April 10, 2020
Preventing Infections by Encapsulated Bacteria Through Vaccine Prophylaxis in Inflammatory Bowel DiseaseMarco Vincenzo Lenti, Caterina Mengoli, Marta Vernero, et al.
Pageof 5